Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Kythera Biopharmaceuticals
This is a single center, open-label, dose-escalation study in which subjects will receive 4 different dosage concentrations (3 dosing paradigms) of ATX-101 in a single dosing session.
Age
18–65
Sex
ALL
Healthy volunteers
Accepted
You may be eligible if
Healthy males or nonpregnant females
Age 18 to 65
Sufficient submental fat for injections
Signed informed consent
You may not be if
Prior interventions in the chin or neck area
History or presence of drug or alcohol abuse
Treatment with an investigational agent within 30 days before the dose
Clareo Health | Dose-Escalation Safety and Pharmacokinetic Study of ATX-101
